ABVC Completes BioKey Cayman Spin-Off, Distributing 4.5M Shares to Shareholders
ABVC is trading near its 52-week low of $0.707 (4.7% above the low).
Summary
ABVC BioPharma completed its BioKey Cayman spin-off, distributing 4.5 million shares (15% of the subsidiary) to ABVC shareholders as a pro rata dividend. ABVC retains 85% control.
Key Events · M&A and Partnerships · ABVC
-
BioKey Cayman Spin-Off Completed
ABVC distributed 4,500,390 ordinary shares of BioKey (Cayman), Inc. to ABVC common stockholders as a pro rata dividend, effective August 21, 2026.
-
Distribution Ratio and Record Date
Shareholders received 0.169464 BioKey ordinary shares for each ABVC share held at the close of business on July 24, 2026.
-
Ownership Structure After Spin-Off
ABVC retains approximately 85% controlling interest in BioKey Cayman; ABVC shareholders collectively hold the remaining 15%.
-
BioKey Cayman to Seek OTC Listing
BioKey Cayman intends to apply for quotation on OTC Markets; no trading symbol has been assigned yet.
Analysis · ABVC · Life Sciences
ABVC BioPharma completed the partial separation of its BioKey (Cayman) subsidiary on August 21, 2026, distributing 4,500,390 ordinary shares — approximately 15% of BioKey Cayman — to ABVC shareholders as a pro rata dividend. Each ABVC shareholder received 0.169464 BioKey shares per ABVC share held on the July 24 record date. ABVC retains an 85% controlling stake. This is the first disclosure of the final distribution terms and share counts, following two prior postponements. The spin-off creates a separate Exchange Act reporting entity that will seek OTC Markets quotation, potentially unlocking value for ABVC holders while reducing ABVC's direct ownership of BioKey Cayman's assets.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1993 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABVC was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $0.71 to $3.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.